Narala Sagar, Nyavanandi Dinesh, Mandati Preethi, Youssef Ahmed Adel Ali, Alzahrani Abdullah, Kolimi Praveen, Zhang Feng, Repka Michael
Department of Pharmaceutics and Drug Delivery, School of Pharmacy, The University of Mississippi, University, MS 38677, USA.
Department of Pharmaceutical Technology, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh 33516, Egypt.
Int J Pharm X. 2022 Dec 28;5:100156. doi: 10.1016/j.ijpx.2022.100156. eCollection 2023 Dec.
This work developed high drug-load pellets for colon targeting in minimal steps by coupling hot-melt extrusion (HME) with a die-surface cutting pelletizer, offering a potential continuous pellet manufacturing process. Ketoprofen (KTP) was selected as a model drug for this study due to its thermal stability and severe upper gastrointestinal side effects. Low and high methoxyl grade pectins were the enzyme-triggered release matrix, and hydroxypropyl methylcellulose (HME 4 M/HME 100LV) was used as a premature release-retarding agent. The powder X-ray diffraction technique and the differential scanning calorimetry results revealed that KTP exists in the solid-solution state within the polymeric matrix after the HME step. The scanning electron micrographs of the fabricated pellets showed a smooth surface without any cracks. The lead formulation showed the lowest premature drug release (∼13%) with an extended KTP release profile over a 24 h period in the presence and absence of the release-triggering enzyme. The lead formulation was stable for 3 months at accelerated stability conditions (40 °C/75 ± 5% RH) concerning drug content, release, and thermal characteristics. In summary, coupling HME and pelletization processes could be a promising technology for developing colon-targeted drug delivery systems.
本研究通过将热熔挤出(HME)与模面切割制粒机相结合,以最少的步骤开发了用于结肠靶向的高载药量微丸,提供了一种潜在的连续微丸制造工艺。由于酮洛芬(KTP)具有热稳定性且存在严重的上消化道副作用,因此被选为该研究的模型药物。低甲氧基和高甲氧基果胶作为酶触发释放基质,羟丙基甲基纤维素(HME 4M/HME 100LV)用作延缓早期释放的试剂。粉末X射线衍射技术和差示扫描量热法结果表明,在HME步骤之后,KTP以固溶体状态存在于聚合物基质中。所制备微丸的扫描电子显微镜照片显示表面光滑,无任何裂缝。在有和没有释放触发酶的情况下,先导配方在24小时内显示出最低的早期药物释放(约13%),且KTP释放曲线延长。在加速稳定性条件(40°C/75±5%RH)下,先导配方在药物含量、释放和热特性方面3个月内保持稳定。总之,将HME和制粒工艺相结合可能是开发结肠靶向给药系统的一种有前景的技术。